Pictet Asset Management (UK)’s Krystal Biotech KRYS Stock Holding History

Pictet Asset Management (UK)’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$37.9M	Buy	557,480 +140,600	+34%	+$9.81M	0.04%	400
2021 Q1	$32.1M	Sell	416,880 -55,097	-12%	-$4.01M	0.04%	416
2020 Q4	$28.3M	Sell	471,977 -7,479	-2%	-$374K	0.04%	419
2020 Q3	$20.6M	Buy	479,456 +272,864	+132%	+$11.9M	0.03%	425
2020 Q2	$8.56M	Buy	206,592 +58,995	+40%	+$2.84M	0.01%	555
2020 Q1	$6.38M	Sell	147,597 -63,582	-30%	-$3.33M	0.01%	577
2019 Q4	$11.7M	Sell	211,179 -11,478	-5%	-$563K	0.02%	546
2019 Q3	$7.73M	Buy	+222,657	New	+$9.95M	0.02%	591

Other funds holding KRYS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Pictet Asset Management (UK)'s KRYS Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its Krystal Biotech (KRYS) stake by 34% in Q2 2021, buying an estimated $9.81M and bringing the position to 557,480 shares worth $37.9M. The position accounts for 0.04% of the portfolio, ranked #400.

Pictet Asset Management (UK) first reported a position in KRYS in Q3 2019 and has held it in 8 quarters since. 113 funds tracked by Wall St. Rank hold KRYS as of Q2 2021.

Pictet Asset Management (UK) held 557,480 shares of Krystal Biotech worth $37.9M as of Q2 2021.
Pictet Asset Management (UK) bought 140,600 Krystal Biotech shares in Q2 2021, an estimated $9.81M.
Krystal Biotech made up 0.04% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #400 holding.
Pictet Asset Management (UK) first reported a position in Krystal Biotech in Q3 2019 and has held it in 8 quarters since.
113 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.